JP2005533830A - トロンボキサンａ２受容体アンタゴニストおよびｃｏｘ−２阻害剤の薬剤の組み合わせ - Google Patents
トロンボキサンａ２受容体アンタゴニストおよびｃｏｘ−２阻害剤の薬剤の組み合わせ Download PDFInfo
- Publication number
- JP2005533830A JP2005533830A JP2004519059A JP2004519059A JP2005533830A JP 2005533830 A JP2005533830 A JP 2005533830A JP 2004519059 A JP2004519059 A JP 2004519059A JP 2004519059 A JP2004519059 A JP 2004519059A JP 2005533830 A JP2005533830 A JP 2005533830A
- Authority
- JP
- Japan
- Prior art keywords
- cox
- inhibitor
- thromboxane
- receptor antagonist
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229940111134 coxibs Drugs 0.000 title claims description 36
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title claims description 36
- 229940123987 Thromboxane A2 receptor antagonist Drugs 0.000 title claims description 25
- 239000003769 thromboxane A2 receptor blocking agent Substances 0.000 title claims description 25
- 239000000890 drug combination Substances 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 28
- 230000036407 pain Effects 0.000 claims abstract description 18
- 206010061218 Inflammation Diseases 0.000 claims abstract description 15
- 230000004054 inflammatory process Effects 0.000 claims abstract description 15
- 102000003938 Thromboxane Receptors Human genes 0.000 claims abstract description 11
- 108090000300 Thromboxane Receptors Proteins 0.000 claims abstract description 11
- 239000003112 inhibitor Substances 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims description 28
- 229940079593 drug Drugs 0.000 claims description 23
- 208000002193 Pain Diseases 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 229960000590 celecoxib Drugs 0.000 claims description 11
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims description 11
- 230000001225 therapeutic effect Effects 0.000 claims description 11
- 229950004274 ifetroban Drugs 0.000 claims description 10
- BBPRUNPUJIUXSE-DXKRWKNPSA-N ifetroban Chemical compound CCCCCNC(=O)C1=COC([C@H]2[C@H]([C@@H]3CC[C@H]2O3)CC=2C(=CC=CC=2)CCC(O)=O)=N1 BBPRUNPUJIUXSE-DXKRWKNPSA-N 0.000 claims description 10
- 229960000371 rofecoxib Drugs 0.000 claims description 10
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims description 10
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 7
- 150000003180 prostaglandins Chemical class 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 206010003178 Arterial thrombosis Diseases 0.000 claims description 5
- 206010020772 Hypertension Diseases 0.000 claims description 5
- 206010047249 Venous thrombosis Diseases 0.000 claims description 5
- DYWAPFDKPAHSED-UHFFFAOYSA-N 2-cycloheptyloxepane Chemical group C1CCCCCC1C1OCCCCC1 DYWAPFDKPAHSED-UHFFFAOYSA-N 0.000 claims description 4
- 206010002383 Angina Pectoris Diseases 0.000 claims description 4
- 206010019233 Headaches Diseases 0.000 claims description 4
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims description 4
- 208000000112 Myalgia Diseases 0.000 claims description 4
- 208000004550 Postoperative Pain Diseases 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 231100000869 headache Toxicity 0.000 claims description 4
- 229960001929 meloxicam Drugs 0.000 claims description 4
- 208000013465 muscle pain Diseases 0.000 claims description 4
- MIMJSJSRRDZIPW-UHFFFAOYSA-N tilmacoxib Chemical compound C=1C=C(S(N)(=O)=O)C(F)=CC=1C=1OC(C)=NC=1C1CCCCC1 MIMJSJSRRDZIPW-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 150000008331 benzenesulfonamides Chemical class 0.000 claims description 3
- HDUWKQUHMUSICC-UHFFFAOYSA-N n-[6-(2,4-difluorophenyl)sulfanyl-1-oxo-2,3-dihydroinden-5-yl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=2CCC(=O)C=2C=C1SC1=CC=C(F)C=C1F HDUWKQUHMUSICC-UHFFFAOYSA-N 0.000 claims description 3
- KTDZCOWXCWUPEO-UHFFFAOYSA-N NS-398 Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1CCCCC1 KTDZCOWXCWUPEO-UHFFFAOYSA-N 0.000 claims description 2
- 208000032382 Ischaemic stroke Diseases 0.000 claims 3
- 230000001052 transient effect Effects 0.000 claims 3
- 150000001408 amides Chemical class 0.000 claims 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 abstract description 20
- 239000000203 mixture Substances 0.000 abstract description 16
- 239000002464 receptor antagonist Substances 0.000 abstract description 6
- 229940044551 receptor antagonist Drugs 0.000 abstract description 6
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 5
- 102000010907 Cyclooxygenase 2 Human genes 0.000 abstract 1
- 208000027753 pain disease Diseases 0.000 abstract 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 19
- 108010037464 Cyclooxygenase 1 Proteins 0.000 description 9
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 9
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 3
- 229960001123 epoprostenol Drugs 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000010695 polyglycol Substances 0.000 description 2
- 229920000151 polyglycol Polymers 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010017886 Gastroduodenal ulcer Diseases 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 231100000029 gastro-duodenal ulcer Toxicity 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 229940077716 histamine h2 receptor antagonists for peptic ulcer and gord Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- -1 troches Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39426802P | 2002-07-09 | 2002-07-09 | |
| PCT/IB2003/002633 WO2004004776A1 (en) | 2002-07-09 | 2003-07-03 | Phamaceutical combination of a thromboxane a2 receptor antagonist and a cox-2 inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005533830A true JP2005533830A (ja) | 2005-11-10 |
| JP2005533830A5 JP2005533830A5 (enExample) | 2006-08-17 |
Family
ID=30115701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004519059A Withdrawn JP2005533830A (ja) | 2002-07-09 | 2003-07-03 | トロンボキサンａ２受容体アンタゴニストおよびｃｏｘ−２阻害剤の薬剤の組み合わせ |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20050020657A1 (enExample) |
| EP (1) | EP1519753A1 (enExample) |
| JP (1) | JP2005533830A (enExample) |
| CN (1) | CN1665538A (enExample) |
| AU (1) | AU2003244913A1 (enExample) |
| CA (1) | CA2491848A1 (enExample) |
| WO (1) | WO2004004776A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010526104A (ja) * | 2007-05-03 | 2010-07-29 | ポルトラ ファーマシューティカルズ，インコーポレイテッド | トロンボキサン受容体アンタゴニストを用いて血栓症を治療及び予防する単位用量製剤及び方法 |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020035107A1 (en) | 2000-06-20 | 2002-03-21 | Stefan Henke | Highly concentrated stable meloxicam solutions |
| DE10161077A1 (de) | 2001-12-12 | 2003-06-18 | Boehringer Ingelheim Vetmed | Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion |
| US8992980B2 (en) | 2002-10-25 | 2015-03-31 | Boehringer Ingelheim Vetmedica Gmbh | Water-soluble meloxicam granules |
| CA2534316A1 (en) * | 2003-08-07 | 2005-02-24 | B.M.R.A. Corporation B.V. | Compositions and methods involving the combination of a thromboxane a2 receptor antagonist and an inhibitor of cyclooxygenase-1 |
| EP1568369A1 (en) | 2004-02-23 | 2005-08-31 | Boehringer Ingelheim Vetmedica Gmbh | Use of meloxicam for the treatment of respiratory diseases in pigs |
| EP1863534A1 (en) * | 2005-03-23 | 2007-12-12 | Boehringer Ingelheim International GmbH | Composition comprising a combined thromboxane receptor antagonist and thromboxane synthase inhibitor and a cox-2 inhibitor |
| US20070037797A1 (en) * | 2005-08-15 | 2007-02-15 | Hellstrom Harold R | Method of reducing the risk of adverse cardiovascular (CV) events associated with the administration of pharmaceutical agents which favor CV events |
| US8188267B2 (en) * | 2008-02-13 | 2012-05-29 | Eastman Chemical Company | Treatment of cellulose esters |
| PL4378443T3 (pl) | 2009-10-12 | 2025-09-08 | Boehringer Ingelheim Vetmedica Gmbh | Pojemniki na kompozycje zawierające meloksykam |
| CA2791805A1 (en) | 2010-03-03 | 2011-09-09 | Boehringer Ingelheim Vetmedica Gmbh | Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats |
| US9795568B2 (en) | 2010-05-05 | 2017-10-24 | Boehringer Ingelheim Vetmedica Gmbh | Low concentration meloxicam tablets |
| EP3804717A1 (en) * | 2014-05-16 | 2021-04-14 | Cumberland Pharmaceuticals, Inc. | Compositions and methods of treating systemic sclerosis or pulmonary arterial hypertension |
| CN114569608A (zh) * | 2015-06-30 | 2022-06-03 | 坎伯兰医药品股份有限公司 | Aerd/哮喘中的血栓烷受体拮抗剂 |
| CN106188245A (zh) * | 2016-08-30 | 2016-12-07 | 苏州普罗达生物科技有限公司 | 血栓烷a2抑制剂多肽及应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK471479A (da) * | 1978-12-13 | 1980-06-14 | Pfizer | Fremgangsmaade til fremstilling af imidazolderivater og salte deraf |
| US5100889A (en) * | 1989-04-03 | 1992-03-31 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease |
| GB9220137D0 (en) * | 1992-09-23 | 1992-11-04 | Pfizer Ltd | Therapeutic agents |
| JPH0753505A (ja) * | 1992-10-01 | 1995-02-28 | Hokuriku Seiyaku Co Ltd | ベンゼンスルホンアミド誘導体及びその用途 |
| US5605917A (en) * | 1994-12-22 | 1997-02-25 | Bristol-Myers Squibb Company | Method of treating dysmenorrhea employing an interphenylene 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analog |
| US6586458B1 (en) * | 1996-08-16 | 2003-07-01 | Pozen Inc. | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
| US5872145A (en) * | 1996-08-16 | 1999-02-16 | Pozen, Inc. | Formulation of 5-HT agonist and NSAID for treatment of migraine |
| US6077539A (en) * | 1996-11-12 | 2000-06-20 | Pozen, Inc. | Treatment of migraine headache |
| CA2407469A1 (en) * | 2000-05-15 | 2001-11-22 | Merck Frosst Canada & Co. | Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor |
| WO2003035063A1 (en) * | 2001-10-25 | 2003-05-01 | Dinesh Shantilal Patel | Novel preparation of selective cyclooxygenase ii inhibitors |
| AU2003247622A1 (en) * | 2002-06-27 | 2004-01-19 | Nitromed, Inc. | Cyclooxygenase-2 selective inhibitors, compositions and methods of use |
-
2003
- 2003-07-03 JP JP2004519059A patent/JP2005533830A/ja not_active Withdrawn
- 2003-07-03 CN CN038161303A patent/CN1665538A/zh active Pending
- 2003-07-03 AU AU2003244913A patent/AU2003244913A1/en not_active Abandoned
- 2003-07-03 CA CA002491848A patent/CA2491848A1/en not_active Abandoned
- 2003-07-03 WO PCT/IB2003/002633 patent/WO2004004776A1/en not_active Ceased
- 2003-07-03 US US10/612,338 patent/US20050020657A1/en not_active Abandoned
- 2003-07-03 EP EP03738386A patent/EP1519753A1/en not_active Ceased
-
2007
- 2007-11-02 US US11/979,450 patent/US20080113973A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010526104A (ja) * | 2007-05-03 | 2010-07-29 | ポルトラ ファーマシューティカルズ，インコーポレイテッド | トロンボキサン受容体アンタゴニストを用いて血栓症を治療及び予防する単位用量製剤及び方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1665538A (zh) | 2005-09-07 |
| CA2491848A1 (en) | 2004-01-15 |
| AU2003244913A1 (en) | 2004-01-23 |
| US20080113973A1 (en) | 2008-05-15 |
| EP1519753A1 (en) | 2005-04-06 |
| US20050020657A1 (en) | 2005-01-27 |
| WO2004004776A1 (en) | 2004-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080113973A1 (en) | Compositions and methods involving the combination of a thromboxane A2 receptor antagonist and an inhibitor of cyclooxygenase-2 | |
| CA2260943C (en) | Formulation of 5-ht agonists | |
| JPH07206712A (ja) | ＨＭＧＣｏＡレダクターゼインヒビターを用いる心臓血管の疾患の発生の危険を予防または減少する方法 | |
| US9662315B2 (en) | Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs | |
| JPH08169823A (ja) | 糖尿病合併症治療用組成物 | |
| JP2005533830A5 (enExample) | ||
| WO2004037254A1 (fr) | Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire | |
| AU1361299A (en) | Combination therapy for reducing the risks associated with cardio-and cerebrovascular disease | |
| US20020147206A1 (en) | Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy | |
| RU2245712C2 (ru) | Применение антагонистов кортизола при лечении сердечной недостаточности | |
| CN110290788A (zh) | 氨基甲酸酯化合物用于预防、缓解或治疗双相障碍的用途 | |
| JP2011525479A (ja) | 非ステロイド性抗炎症性化合物と降圧化合物とを組み合わせた製剤処方及びその使用方法 | |
| US20110034424A1 (en) | Method for the long term nsaid use | |
| EP1656940A1 (en) | Angiotensin II receptor antagonists for treating vascular headache conditions | |
| US20060142288A1 (en) | Combinations and methods for headaches | |
| AU2022294728A1 (en) | Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid | |
| EP0971714B1 (en) | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia | |
| US20050059741A1 (en) | Compositions and methods involving the combination of a thromboxane A2 receptor antagonist and an inhibitor of cyclooxygenase-1 | |
| HK1080750A (en) | Pharmaceutical combination of a thromboxane a2 receptor antagonist and a cox-2 inhibitor | |
| JP2011032262A (ja) | Ｎｓａｉｄの長期使用のための医薬組成物 | |
| JP4677705B2 (ja) | 頭痛の予防および／または治療剤 | |
| US20020058688A1 (en) | Method of using cyclooxegenase-2 inhibitors in the treatment and prevention of dementia | |
| JP2005503346A (ja) | 片頭痛を治療するための方法及び組成物 | |
| EP3725312A1 (en) | New chemical compound containing active enantiomer s-(-) ketorolac tromethamine for the treatment of pain | |
| HK40015213A (en) | Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060629 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060629 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20080617 |